NCT01263548: To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder |
|
|
| Completed | N/A | 45 | Canada | lisdexamfetamine dimesylate, Vyvanse | University Health Network, Toronto, Shire | Attention Deficit/Hyperactivity Disorder, Bipolar Disorder | 01/12 | 01/12 | | |